吉西他滨联合雷替曲塞治疗局部晚期或转移性胰腺腺癌的I/II期研究

Michael Agnieszka, M. Hill, A. Maraveyas, H. Wasan, F. Lofts
{"title":"吉西他滨联合雷替曲塞治疗局部晚期或转移性胰腺腺癌的I/II期研究","authors":"Michael Agnieszka, M. Hill, A. Maraveyas, H. Wasan, F. Lofts","doi":"10.5580/250a","DOIUrl":null,"url":null,"abstract":"Adenocarcinoma of the pancreas remains one of the most difficult cancers to treat. Raltitrexed, a novel quinazoline analogue, combined with gemcitabine is likely to potentate the anti-cancer effect, as both of those drugs inhibit DNA synthesis via separate metabolic pathway. We report a phase I/II study of increasing dose of gemcitabine with raltitrexed in patients with advanced adenocarcinoma of the pancreas. The study was conducted at three different dose levels with raltitrexed at 3mg/m2 and increasing gemcitabine levels. 24 patients were recruited. Cohort 2 patient developed unexpected toxicity with 58% of patients experiencing haematological toxicity and 29% nausea and vomiting. The majority of patients complained of lethargy and 5 patients reached dose-limiting toxicity. Partial responses were documented in two out of 24 patients (8%), 25% had stable disease and 50% developed progressive disease. We found the combination of raltitrexed and gemcitabine active but poorly tolerated in pancreatic cancer.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":"43 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2005-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Phase I/II Study to Investigate the Use of Gemcitabine in Combination with Raltitrexed in Locally Advanced or Metastatic Pancreatic Adenocarcinoma\",\"authors\":\"Michael Agnieszka, M. Hill, A. Maraveyas, H. Wasan, F. Lofts\",\"doi\":\"10.5580/250a\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Adenocarcinoma of the pancreas remains one of the most difficult cancers to treat. Raltitrexed, a novel quinazoline analogue, combined with gemcitabine is likely to potentate the anti-cancer effect, as both of those drugs inhibit DNA synthesis via separate metabolic pathway. We report a phase I/II study of increasing dose of gemcitabine with raltitrexed in patients with advanced adenocarcinoma of the pancreas. The study was conducted at three different dose levels with raltitrexed at 3mg/m2 and increasing gemcitabine levels. 24 patients were recruited. Cohort 2 patient developed unexpected toxicity with 58% of patients experiencing haematological toxicity and 29% nausea and vomiting. The majority of patients complained of lethargy and 5 patients reached dose-limiting toxicity. Partial responses were documented in two out of 24 patients (8%), 25% had stable disease and 50% developed progressive disease. We found the combination of raltitrexed and gemcitabine active but poorly tolerated in pancreatic cancer.\",\"PeriodicalId\":22534,\"journal\":{\"name\":\"The Internet Journal of Oncology\",\"volume\":\"43 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2005-12-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Internet Journal of Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5580/250a\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Internet Journal of Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5580/250a","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

胰腺腺癌仍然是最难治疗的癌症之一。雷替曲塞是一种新型喹唑啉类似物,与吉西他滨联合可能会增强抗癌作用,因为这两种药物都通过不同的代谢途径抑制DNA合成。我们报告了一项I/II期研究,增加吉西他滨与雷替曲塞在晚期胰腺腺癌患者中的剂量。该研究在三种不同剂量水平下进行,雷曲塞为3mg/m2,吉西他滨逐渐增加。共招募了24名患者。队列2患者出现意想不到的毒性,58%的患者出现血液学毒性,29%的患者出现恶心和呕吐。多数患者表现为嗜睡,5例达到剂量限制性毒性。24例患者中有2例(8%)出现部分缓解,25%的患者病情稳定,50%的患者病情进展。我们发现雷替曲塞和吉西他滨联合治疗胰腺癌有效,但耐受性差。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Phase I/II Study to Investigate the Use of Gemcitabine in Combination with Raltitrexed in Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Adenocarcinoma of the pancreas remains one of the most difficult cancers to treat. Raltitrexed, a novel quinazoline analogue, combined with gemcitabine is likely to potentate the anti-cancer effect, as both of those drugs inhibit DNA synthesis via separate metabolic pathway. We report a phase I/II study of increasing dose of gemcitabine with raltitrexed in patients with advanced adenocarcinoma of the pancreas. The study was conducted at three different dose levels with raltitrexed at 3mg/m2 and increasing gemcitabine levels. 24 patients were recruited. Cohort 2 patient developed unexpected toxicity with 58% of patients experiencing haematological toxicity and 29% nausea and vomiting. The majority of patients complained of lethargy and 5 patients reached dose-limiting toxicity. Partial responses were documented in two out of 24 patients (8%), 25% had stable disease and 50% developed progressive disease. We found the combination of raltitrexed and gemcitabine active but poorly tolerated in pancreatic cancer.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Dermatofibrosarcoma Protuberans: A Deceptive Neoplasm. Internal Mammary Node Evaluation And Elective Nodal Treatment In Medial Breast Cancers: A Case Report And Review Of The Literature. Adjuvant Radiation Therapy For Wedge-Resected Non-Small Cell Lung Cancer Adjacent To A Large Thoracic Aortic Aneurysm: A Case Report And Review Of The Literature Acute Pancreatitis Following VAD Chemotherapy Combination Consisting Of Vincristine, Doxorubicin, And Dexamethasone In A Newly Diagnosed Multiple Myeloma Patient: A Case Report. A Rare Case Of Dysgerminoma In A 58-Year Old Postmenopausal Woman In Makurdi, North Central Nigeria.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1